Quick Dispatch:
Your surmount-1 tirzepatide non-diabetic obesity trial Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 tirzepatide non-diabetic obesity trial Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about surmount-1 tirzepatide non-diabetic obesity trial Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 tirzepatide non-diabetic obesity trial Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
Weight reduction with different doses of Tirzepatide in Surmount 1
24.40
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
26.90
For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The
22.43
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
27.83
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
29.23
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
23.25
Clinical trials of subcutaneous tirzepatide (SURMOUNT-1, -2 and -3
25.95
